Edoxaban monotherapy superior to dual therapy in patients with high-risk AF and stable CAD

Edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic therapy, in patients with high-risk atrial fibrillation (AF) and stable coronary artery disease (CAD), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

Medicaid startup Waymark publishes study proving its program slashes ER visits

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 17, 2024

Express Scripts overcharged postal workers by $45 million, audit says

Express Scripts, one of the largest pharmacy benefit managers in the country, overcharged U.S. Postal Service employees by a whopping $45 million for their prescription

July 22, 2024

Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis | Psychedelic Invest

–Human tissue study assessed SPU-21’s efficiency, optimization, and binding affinity– Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics

October 16, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.